Biofrontera about to crush it come January

Discussion in 'Sun Pharma' started by anonymous, Sep 25, 2017 at 9:57 AM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    Biofrontera Grows Revenues and Improves Financial Position in First Half 2017
    Leverkusen, Germany, August 31, 2017 – Biofrontera AG (FSE: B8F), the specialist for the treatment of sun-induced skin cancer , today reported its financial results for the second quarter and first half ended June 30, 2017 and provided an update on recent operational and clinical developments.
    “The first half of 2017 proved to be a great success as we grew our total revenues by 193% year-over-year to €5 million, driven primarily by our sales in the U.S. In the second quarter we took additional steps to further strengthen our momentum and improve the efficiency and effectiveness of our U.S. sales operations to drive adoption of Ameluz® by dermatologists. Additionally, as we seek to expand our market opportunity, we remain excited about the prospects for a basal cell carcinoma label extension with an efficient and less costly clinical development plan recently agreed upon with the FDA. In Europe, the approval from the European Commission for a label extension to include BCC reinforces our position in the PDT market and expands the reach of Ameluz® into hospitals where dermatologists are based in most countries in Europe. We also look forward to a positive opinion from the European Medicines Agency by the end of 2017 or early 2018 for our recently submitted application to expand the label of Ameluz® to include daylight-PDT. With the support of recent capital raises and the loan from the European Investment Bank, we believe that we have significant opportunities to continue to grow in all of our markets and expand our indications in order to support future growth,” commented Prof. Dr. Hermann Lübbert, CEO of Biofrontera.
    Second Quarter and First Half 2017 Financial Highlights:
    • Sales increased by 193% to €5.0 million in H1 2017, compared to €1.7 million in the same period 2016.
    • Generated €2.4 million in revenues in U.S. in H1 2017, in line with expectations.
    • Research and development costs increased to €2.2 million in H1 2017 (up 18%), mainly due to costs incurred as part of the development partnership with Maruho.
    • Net loss was €8.1 million in H1 2017
     
  2. anonymous

    anonymous Guest

    I wouldn't go that far to say they're crushing it, but no doubt the first half of next year could be big for Biofrontera.

    Pent up frustration will mean a serious backlash - our customers are already talking about January and their new J code.
     
  3. anonymous

    anonymous Guest


    They made enough in 2017 to survive. In 2018 they will thrive because we jacked with our customers so much. How about another 40% increase in price? That will come back to bite us hard.
     
  4. anonymous

    anonymous Guest

    that's what I'm afraid of.
    They're in the black and building momentum. Our price increases are killing stick volume and customers are going to seek revenge.
     
  5. anonymous

    anonymous Guest

    Microphone drop
     
  6. anonymous

    anonymous Guest

    Zero talent reps and management.
     
  7. anonymous

    anonymous Guest

    Dear Christoph:

    What is happening in the field is not acceptable. PDT season is NOW. The field needs leadership, 2018 has been spent entirely putting out Holm/ Rose created fires. If not resolved quickly, the problem is on your watch. Biofrontera: where opportunities come to be squandered.
     
  8. anonymous

    anonymous Guest

    Not knowing PDT or US Buy/ Bill he will just continue to double down on his previous errors.

    Tick, tock, tick, tock.......house is on fire
     
  9. anonymous

    anonymous Guest

    Which mistake?! Become a little more precise!!!!

    I think there are currently rapidly gaining market share.
     
  10. anonymous

    anonymous Guest

    RE: Sun PDT sales rep or (the 7 still at that dumpster fire) looking for intel.

    Please blog elsewhere and worry about your own business. Nothing to see here:)
     
  11. anonymous

    anonymous Guest

    We are now at the NASDAQ! A few more weeks and we overran you !!

    BIOFRONTERA RULES!!!!!!!!
     
  12. anonymous

    anonymous Guest

    Objectively speaking, the spirit and culture at BF is what we thought we were going to have at SUN.

    #prettycoolplacetobe
     
  13. anonymous

    anonymous Guest

    DW, get off cafepharma!
     
  14. anonymous

    anonymous Guest

    DESTROYED in a few month.

    Ridiculous indian clowns
     
  15. anonymous

    anonymous Guest

    DW, don’t you have a TM spot to fill in San Francisco? Get back to work and get off cafepharma.